Daiichi Sankyo Inc Drug Patent Portfolio

Daiichi Sankyo Inc's Family Patents


Family Patents



Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Daiichi Sankyo Inc News

Resolution Reached in Patent Conflict Between Daiichi Sankyo and Seagen Regarding Cancer Treatment

07 Apr, 2026

CNIPA supports generic pharmaceutical company in conflict regarding mirogabalin besylate tablets.

29 Jan, 2026

Federal Circuit Invalidates Life Sciences Patent Due to Inadequate Disclosure of Specific Species

16 Jan, 2026

Federal Circuit Invalidates Life Sciences Patent Due to Inadequate Disclosure of Specific Species

16 Jan, 2026

See More